Literature DB >> 7589780

Desethylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone alpha 1-receptor protein.

H C van Beeren1, O Bakker, W M Wiersinga.   

Abstract

Desethylamiodarone (DEA), the major metabolite of the potent antiarrythmic drug amiodarone, is a non-competitive inhibitor of the binding of thyroid hormone (T3) to the beta 1-thyroid hormone receptor (T3R). In the present study, we investigated whether DEA acts in a similar way with respect to the alpha 1-T3R. The chicken alpha 1-T3R, expressed in an E. coli system, was incubated in the presence or absence of DEA with [125I]T3 in buffer containing 0.05% Triton X-100, 0.05% BSA and 1% ethanol (v/v) in order to solubilise DEA. DEA, but not amiodarone, inhibited T3 binding in a dose-dependent manner; the IC50 value was 3.5 x 10(-5) M. Scatchard analyses in the presence of DEA demonstrated a dose-dependent decrease in Ka values, but no change in MBC. Lineweaver-Burk plots clearly indicated competitive inhibition by DEA. Pre-incubation of the alpha 1-receptor with DEA decreased maximal [125I]T3 binding, which was independent of the duration of pre-incubation. In conclusion, in contrast to the beta 1-T3R, where DEA acts as a non-competitive inhibitor, we now report as a new finding the competitive action of DEA to the alpha 1-T3R.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589780     DOI: 10.1016/0303-7207(95)03578-u

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  10 in total

1.  Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment.

Authors:  Matthew L Rosene; Gábor Wittmann; Rafael Arrojo e Drigo; Praful S Singru; Ronald M Lechan; Antonio C Bianco
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

Review 2.  Paradigms of Dynamic Control of Thyroid Hormone Signaling.

Authors:  Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

Review 3.  Amiodarone and the thyroid: a 2012 update.

Authors:  F Bogazzi; L Tomisti; L Bartalena; F Aghini-Lombardi; E Martino
Journal:  J Endocrinol Invest       Date:  2012-03-19       Impact factor: 4.256

4.  Interaction of amiodarone and triiodothyronine on the expression of beta-adrenoceptors in brown adipose tissue of rat.

Authors:  H Adli; R Bazin; G Y Perret
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

5.  Management of amiodarone-related thyroid problems.

Authors:  Shashithej K Narayana; David R Woods; Christopher J Boos
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

Review 6.  Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy.

Authors:  C M Newman; A Price; D W Davies; T A Gray; A P Weetman
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

Review 7.  [Thyroid and treatment with amiodarone diagnosis, therapy and clinical management].

Authors:  Peter Mikosch
Journal:  Wien Med Wochenschr       Date:  2008

8.  Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites.

Authors:  Aaron N Snead; Motonori Miyakawa; Edwin S Tan; Thomas S Scanlan
Journal:  Bioorg Med Chem Lett       Date:  2008-08-09       Impact factor: 2.823

Review 9.  Thyroid hormone, brain development, and the environment.

Authors:  Thomas R Zoeller; Amy L S Dowling; Carolyn T A Herzig; Eric A Iannacone; Kelly J Gauger; Ruby Bansal
Journal:  Environ Health Perspect       Date:  2002-06       Impact factor: 9.031

Review 10.  The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches.

Authors:  Wilmar M Wiersinga
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.